These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20737546)

  • 21. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis.
    Talarico-Filho S; Mendonça DO Nascimento M; Sperandeo DE Macedo F; DE Sanctis Pecora C
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S44-50. PubMed ID: 17241414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
    Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
    Shearer JD; Vassar ML; Swiderski W; Metcalfe K; Niemuth N; Henderson I
    Vaccine; 2010 Oct; 28(45):7313-8. PubMed ID: 20816903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis.
    Fabbri M; Leodori G; Fernandes RM; Bhidayasiri R; Marti MJ; Colosimo C; Ferreira JJ
    Neurotox Res; 2016 Jan; 29(1):105-17. PubMed ID: 26467676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.
    Farrell R; Kapoor R; Leary S; Rudge P; Thompson A; Miller D; Giovannoni G
    Mult Scler; 2008 Mar; 14(2):212-8. PubMed ID: 17986510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence.
    Jandhyala R
    J Drugs Dermatol; 2012 Jun; 11(6):731-6. PubMed ID: 22648220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
    Monheit GD; Cohen JL;
    J Am Acad Dermatol; 2009 Sep; 61(3):421-5. PubMed ID: 19577326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.
    Sankhla C; Jankovic J; Duane D
    Mov Disord; 1998 Jan; 13(1):150-4. PubMed ID: 9452341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of Botox and a Chinese type a botulinum toxin in cervical dystonia].
    Wan X; Tang X
    Zhonghua Yi Xue Za Zhi; 1998 Feb; 78(2):131-4. PubMed ID: 10923426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study.
    Heckmann M; Plewig G;
    Arch Dermatol; 2005 Oct; 141(10):1255-9. PubMed ID: 16230563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
    Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
    Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
    Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
    Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
    Gneiss C; Koudouovoh-Tripp PM; Ropele S; Gotwald T; Ehling R; Lutterotti A; Aichner F; Ladurner G; Eggers C; Schautzer F; Künz B; Millonig A; Aspeck E; Reindl M; Berger T; Fazekas F; Deisenhammer F
    Mult Scler; 2009 Dec; 15(12):1481-8. PubMed ID: 19965519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
    van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
    Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum Toxin Type A Immunogenicity across Multiple Indications: An Overview Systematic Review.
    Rahman E; Banerjee PS; Asghar A; Gupta NK; Mosahebi A
    Plast Reconstr Surg; 2022 Apr; 149(4):837-848. PubMed ID: 35139064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of psychological treatments of pathological gambling: a review and meta-analysis.
    Pallesen S; Mitsem M; Kvale G; Johnsen BH; Molde H
    Addiction; 2005 Oct; 100(10):1412-22. PubMed ID: 16185203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.